Cefalexin (UTI / GBS Prophylaxis in Pregnancy)
Brand names: Ceporex, Keflex
Cefalexin is an oral first-generation cephalosporin antibiotic, used in pregnancy for lower urinary tract infection and as intrapartum or antenatal prophylaxis against group B streptococcus when penicillin is unsuitable.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan cross-linking, producing a bactericidal effect against susceptible Gram-positive and many Gram-negative organisms.
Prescribing in practice
- Avoid in patients with a history of immediate or severe hypersensitivity to penicillins or cephalosporins; the risk of cross-reactivity is low but clinically significant reactions can occur.
- Cefalexin is considered suitable in all trimesters of pregnancy and during breastfeeding, making it a useful option for UTI and group B streptococcus cover.
- Confirm susceptibility on culture where possible, as resistance among urinary coliforms is common.
Monitoring
Routine laboratory monitoring is not required, but review the clinical response and any culture and sensitivity results, and watch for signs of antibiotic-associated diarrhoea.
Counselling the patient
- Complete the full prescribed course even if symptoms settle quickly.
- Report severe or persistent diarrhoea, which may indicate Clostridioides difficile infection.
- Seek urgent advice for any rash, swelling or breathing difficulty after a dose.
Evidence & guidelines
Cefalexin is a long-established cephalosporin with a reassuring safety record in pregnancy and is widely recommended for UTI and as an alternative for group B streptococcus prophylaxis.
Reference: RCOG Green-top 36 (Group B Streptococcal Disease 2017); NICE NG112 (UTI in Adults); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Caprini Score for VTE Risk (2005) · VTE Risk
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Caprini VTE Risk Assessment · Venous Thromboembolism
- Khorana Score for VTE in Cancer · VTE Risk
- IMPROVE-DD VTE Risk Score · VTE Risk
- Padua Prediction Score for VTE Risk in Medical Inpatients · Venous Thromboembolism